Loading…
Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial
The purpose of this study was to evaluate the 5-year follow-up (FU) data of the THUNDER (Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries). The THUNDER trial was the first study to investigate the treatment of femoropopliteal arteries with a paclitaxel-coated balloo...
Saved in:
Published in: | JACC. Cardiovascular interventions 2015-01, Vol.8 (1 Pt A), p.102-108 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 108 |
container_issue | 1 Pt A |
container_start_page | 102 |
container_title | JACC. Cardiovascular interventions |
container_volume | 8 |
creator | Tepe, Gunnar Schnorr, Beatrix Albrecht, Thomas Brechtel, Klaus Claussen, Claus D Scheller, Bruno Speck, Ulrich Zeller, Thomas |
description | The purpose of this study was to evaluate the 5-year follow-up (FU) data of the THUNDER (Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries).
The THUNDER trial was the first study to investigate the treatment of femoropopliteal arteries with a paclitaxel-coated balloon (PCB).
In 154 patients, femoropopliteal arteries were treated with PCB, with angioplasty with paclitaxel in contrast medium, or no paclitaxel (control). The primary endpoint was 6-month late lumen loss (LLL). Secondary endpoints included freedom from target lesion revascularization (TLR), binary restenosis rate, and amputation. The 5-year FU compares outcomes in patients treated with PCB and control subjects. Additionally, LLL at 6 months and TLR up to 5-year FU were analyzed in terms of sex and lesion length.
Over the 5-year period, the cumulative number of patients with TLR remained significantly lower in the PCB group (21%) than in the control group (56%, p = 0.0005). In the small group of patients with angiographic and duplex sonographic follow-up, PCB was associated with a lower rate of binary restenosis (17% vs. 54%; p = 0.04). No signs of aneurysm formation or constrictive fibrosis were detected. Whereas LLL at 6-month FU did not differ between men and women in the PCB group, the TLR rate was lower in men than in women at 5-year FU. A benefit of PCB treatment in terms of LLL and TLR was seen independent of lesion length.
The reduced TLR rate following PCB treatment was maintained over the 5-year FU period. No signs of drug-related local vessel abnormalities were detected. (Thunder Trial-Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries [THUNDER]; NCT00156624). |
doi_str_mv | 10.1016/j.jcin.2014.07.023 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1652434830</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1652434830</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-89ee4872e5726c0003225d24b7d42ba0293fdf9a9c7f71cd5318361feca0e27a3</originalsourceid><addsrcrecordid>eNo1kE9LwzAchoMgbk6_gAfJ0Utq_rRJ623odMJQkO1c0vaXrSVdapIy9u2dOE8vPDw8hxehO0YTRpl87JKubvcJpyxNqEooFxdoynIliZI0m6DrEDpKJS0Uv0ITnkkmc86nqJvvt60brA7xiJ3BBnrntSXDibURtMXaR_AtBHxo4w43ftyS2ukIDa60tc7twxPOyBG0x8adwIGMw28p7gCvl5uPl8UXjr7V9gZdGm0D3J53hjavi_Xzkqw-396f5ysycMYiyQuANFccMsVlTSkVnGcNTyvVpLzSlBfCNKbQRa2MYnWTCZYLyQzUmgJXWszQw1938O57hBDLvg01WKv34MZQMpnxVKS5oCf1_qyOVQ9NOfi21_5Y_v8jfgAd1Ga-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1652434830</pqid></control><display><type>article</type><title>Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial</title><source>BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS</source><creator>Tepe, Gunnar ; Schnorr, Beatrix ; Albrecht, Thomas ; Brechtel, Klaus ; Claussen, Claus D ; Scheller, Bruno ; Speck, Ulrich ; Zeller, Thomas</creator><creatorcontrib>Tepe, Gunnar ; Schnorr, Beatrix ; Albrecht, Thomas ; Brechtel, Klaus ; Claussen, Claus D ; Scheller, Bruno ; Speck, Ulrich ; Zeller, Thomas</creatorcontrib><description>The purpose of this study was to evaluate the 5-year follow-up (FU) data of the THUNDER (Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries).
The THUNDER trial was the first study to investigate the treatment of femoropopliteal arteries with a paclitaxel-coated balloon (PCB).
In 154 patients, femoropopliteal arteries were treated with PCB, with angioplasty with paclitaxel in contrast medium, or no paclitaxel (control). The primary endpoint was 6-month late lumen loss (LLL). Secondary endpoints included freedom from target lesion revascularization (TLR), binary restenosis rate, and amputation. The 5-year FU compares outcomes in patients treated with PCB and control subjects. Additionally, LLL at 6 months and TLR up to 5-year FU were analyzed in terms of sex and lesion length.
Over the 5-year period, the cumulative number of patients with TLR remained significantly lower in the PCB group (21%) than in the control group (56%, p = 0.0005). In the small group of patients with angiographic and duplex sonographic follow-up, PCB was associated with a lower rate of binary restenosis (17% vs. 54%; p = 0.04). No signs of aneurysm formation or constrictive fibrosis were detected. Whereas LLL at 6-month FU did not differ between men and women in the PCB group, the TLR rate was lower in men than in women at 5-year FU. A benefit of PCB treatment in terms of LLL and TLR was seen independent of lesion length.
The reduced TLR rate following PCB treatment was maintained over the 5-year FU period. No signs of drug-related local vessel abnormalities were detected. (Thunder Trial-Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries [THUNDER]; NCT00156624).</description><identifier>EISSN: 1876-7605</identifier><identifier>DOI: 10.1016/j.jcin.2014.07.023</identifier><identifier>PMID: 25616822</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Amputation ; Angioplasty, Balloon - adverse effects ; Angioplasty, Balloon - instrumentation ; Cardiovascular Agents - administration & dosage ; Coated Materials, Biocompatible ; Constriction, Pathologic ; Equipment Design ; Female ; Femoral Artery - diagnostic imaging ; Humans ; Limb Salvage ; Male ; Middle Aged ; Paclitaxel - administration & dosage ; Peripheral Arterial Disease - diagnosis ; Peripheral Arterial Disease - therapy ; Popliteal Artery - diagnostic imaging ; Predictive Value of Tests ; Radiography ; Recurrence ; Risk Factors ; Sex Factors ; Time Factors ; Treatment Outcome ; Ultrasonography, Doppler, Duplex ; Vascular Access Devices</subject><ispartof>JACC. Cardiovascular interventions, 2015-01, Vol.8 (1 Pt A), p.102-108</ispartof><rights>Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25616822$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tepe, Gunnar</creatorcontrib><creatorcontrib>Schnorr, Beatrix</creatorcontrib><creatorcontrib>Albrecht, Thomas</creatorcontrib><creatorcontrib>Brechtel, Klaus</creatorcontrib><creatorcontrib>Claussen, Claus D</creatorcontrib><creatorcontrib>Scheller, Bruno</creatorcontrib><creatorcontrib>Speck, Ulrich</creatorcontrib><creatorcontrib>Zeller, Thomas</creatorcontrib><title>Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial</title><title>JACC. Cardiovascular interventions</title><addtitle>JACC Cardiovasc Interv</addtitle><description>The purpose of this study was to evaluate the 5-year follow-up (FU) data of the THUNDER (Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries).
The THUNDER trial was the first study to investigate the treatment of femoropopliteal arteries with a paclitaxel-coated balloon (PCB).
In 154 patients, femoropopliteal arteries were treated with PCB, with angioplasty with paclitaxel in contrast medium, or no paclitaxel (control). The primary endpoint was 6-month late lumen loss (LLL). Secondary endpoints included freedom from target lesion revascularization (TLR), binary restenosis rate, and amputation. The 5-year FU compares outcomes in patients treated with PCB and control subjects. Additionally, LLL at 6 months and TLR up to 5-year FU were analyzed in terms of sex and lesion length.
Over the 5-year period, the cumulative number of patients with TLR remained significantly lower in the PCB group (21%) than in the control group (56%, p = 0.0005). In the small group of patients with angiographic and duplex sonographic follow-up, PCB was associated with a lower rate of binary restenosis (17% vs. 54%; p = 0.04). No signs of aneurysm formation or constrictive fibrosis were detected. Whereas LLL at 6-month FU did not differ between men and women in the PCB group, the TLR rate was lower in men than in women at 5-year FU. A benefit of PCB treatment in terms of LLL and TLR was seen independent of lesion length.
The reduced TLR rate following PCB treatment was maintained over the 5-year FU period. No signs of drug-related local vessel abnormalities were detected. (Thunder Trial-Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries [THUNDER]; NCT00156624).</description><subject>Aged</subject><subject>Amputation</subject><subject>Angioplasty, Balloon - adverse effects</subject><subject>Angioplasty, Balloon - instrumentation</subject><subject>Cardiovascular Agents - administration & dosage</subject><subject>Coated Materials, Biocompatible</subject><subject>Constriction, Pathologic</subject><subject>Equipment Design</subject><subject>Female</subject><subject>Femoral Artery - diagnostic imaging</subject><subject>Humans</subject><subject>Limb Salvage</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Paclitaxel - administration & dosage</subject><subject>Peripheral Arterial Disease - diagnosis</subject><subject>Peripheral Arterial Disease - therapy</subject><subject>Popliteal Artery - diagnostic imaging</subject><subject>Predictive Value of Tests</subject><subject>Radiography</subject><subject>Recurrence</subject><subject>Risk Factors</subject><subject>Sex Factors</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Ultrasonography, Doppler, Duplex</subject><subject>Vascular Access Devices</subject><issn>1876-7605</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNo1kE9LwzAchoMgbk6_gAfJ0Utq_rRJ623odMJQkO1c0vaXrSVdapIy9u2dOE8vPDw8hxehO0YTRpl87JKubvcJpyxNqEooFxdoynIliZI0m6DrEDpKJS0Uv0ITnkkmc86nqJvvt60brA7xiJ3BBnrntSXDibURtMXaR_AtBHxo4w43ftyS2ukIDa60tc7twxPOyBG0x8adwIGMw28p7gCvl5uPl8UXjr7V9gZdGm0D3J53hjavi_Xzkqw-396f5ysycMYiyQuANFccMsVlTSkVnGcNTyvVpLzSlBfCNKbQRa2MYnWTCZYLyQzUmgJXWszQw1938O57hBDLvg01WKv34MZQMpnxVKS5oCf1_qyOVQ9NOfi21_5Y_v8jfgAd1Ga-</recordid><startdate>201501</startdate><enddate>201501</enddate><creator>Tepe, Gunnar</creator><creator>Schnorr, Beatrix</creator><creator>Albrecht, Thomas</creator><creator>Brechtel, Klaus</creator><creator>Claussen, Claus D</creator><creator>Scheller, Bruno</creator><creator>Speck, Ulrich</creator><creator>Zeller, Thomas</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201501</creationdate><title>Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial</title><author>Tepe, Gunnar ; Schnorr, Beatrix ; Albrecht, Thomas ; Brechtel, Klaus ; Claussen, Claus D ; Scheller, Bruno ; Speck, Ulrich ; Zeller, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-89ee4872e5726c0003225d24b7d42ba0293fdf9a9c7f71cd5318361feca0e27a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Amputation</topic><topic>Angioplasty, Balloon - adverse effects</topic><topic>Angioplasty, Balloon - instrumentation</topic><topic>Cardiovascular Agents - administration & dosage</topic><topic>Coated Materials, Biocompatible</topic><topic>Constriction, Pathologic</topic><topic>Equipment Design</topic><topic>Female</topic><topic>Femoral Artery - diagnostic imaging</topic><topic>Humans</topic><topic>Limb Salvage</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Paclitaxel - administration & dosage</topic><topic>Peripheral Arterial Disease - diagnosis</topic><topic>Peripheral Arterial Disease - therapy</topic><topic>Popliteal Artery - diagnostic imaging</topic><topic>Predictive Value of Tests</topic><topic>Radiography</topic><topic>Recurrence</topic><topic>Risk Factors</topic><topic>Sex Factors</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Ultrasonography, Doppler, Duplex</topic><topic>Vascular Access Devices</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tepe, Gunnar</creatorcontrib><creatorcontrib>Schnorr, Beatrix</creatorcontrib><creatorcontrib>Albrecht, Thomas</creatorcontrib><creatorcontrib>Brechtel, Klaus</creatorcontrib><creatorcontrib>Claussen, Claus D</creatorcontrib><creatorcontrib>Scheller, Bruno</creatorcontrib><creatorcontrib>Speck, Ulrich</creatorcontrib><creatorcontrib>Zeller, Thomas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>JACC. Cardiovascular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tepe, Gunnar</au><au>Schnorr, Beatrix</au><au>Albrecht, Thomas</au><au>Brechtel, Klaus</au><au>Claussen, Claus D</au><au>Scheller, Bruno</au><au>Speck, Ulrich</au><au>Zeller, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial</atitle><jtitle>JACC. Cardiovascular interventions</jtitle><addtitle>JACC Cardiovasc Interv</addtitle><date>2015-01</date><risdate>2015</risdate><volume>8</volume><issue>1 Pt A</issue><spage>102</spage><epage>108</epage><pages>102-108</pages><eissn>1876-7605</eissn><abstract>The purpose of this study was to evaluate the 5-year follow-up (FU) data of the THUNDER (Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries).
The THUNDER trial was the first study to investigate the treatment of femoropopliteal arteries with a paclitaxel-coated balloon (PCB).
In 154 patients, femoropopliteal arteries were treated with PCB, with angioplasty with paclitaxel in contrast medium, or no paclitaxel (control). The primary endpoint was 6-month late lumen loss (LLL). Secondary endpoints included freedom from target lesion revascularization (TLR), binary restenosis rate, and amputation. The 5-year FU compares outcomes in patients treated with PCB and control subjects. Additionally, LLL at 6 months and TLR up to 5-year FU were analyzed in terms of sex and lesion length.
Over the 5-year period, the cumulative number of patients with TLR remained significantly lower in the PCB group (21%) than in the control group (56%, p = 0.0005). In the small group of patients with angiographic and duplex sonographic follow-up, PCB was associated with a lower rate of binary restenosis (17% vs. 54%; p = 0.04). No signs of aneurysm formation or constrictive fibrosis were detected. Whereas LLL at 6-month FU did not differ between men and women in the PCB group, the TLR rate was lower in men than in women at 5-year FU. A benefit of PCB treatment in terms of LLL and TLR was seen independent of lesion length.
The reduced TLR rate following PCB treatment was maintained over the 5-year FU period. No signs of drug-related local vessel abnormalities were detected. (Thunder Trial-Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries [THUNDER]; NCT00156624).</abstract><cop>United States</cop><pmid>25616822</pmid><doi>10.1016/j.jcin.2014.07.023</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | EISSN: 1876-7605 |
ispartof | JACC. Cardiovascular interventions, 2015-01, Vol.8 (1 Pt A), p.102-108 |
issn | 1876-7605 |
language | eng |
recordid | cdi_proquest_miscellaneous_1652434830 |
source | BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS |
subjects | Aged Amputation Angioplasty, Balloon - adverse effects Angioplasty, Balloon - instrumentation Cardiovascular Agents - administration & dosage Coated Materials, Biocompatible Constriction, Pathologic Equipment Design Female Femoral Artery - diagnostic imaging Humans Limb Salvage Male Middle Aged Paclitaxel - administration & dosage Peripheral Arterial Disease - diagnosis Peripheral Arterial Disease - therapy Popliteal Artery - diagnostic imaging Predictive Value of Tests Radiography Recurrence Risk Factors Sex Factors Time Factors Treatment Outcome Ultrasonography, Doppler, Duplex Vascular Access Devices |
title | Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T04%3A34%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Angioplasty%20of%20femoral-popliteal%20arteries%20with%20drug-coated%20balloons:%205-year%20follow-up%20of%20the%20THUNDER%20trial&rft.jtitle=JACC.%20Cardiovascular%20interventions&rft.au=Tepe,%20Gunnar&rft.date=2015-01&rft.volume=8&rft.issue=1%20Pt%20A&rft.spage=102&rft.epage=108&rft.pages=102-108&rft.eissn=1876-7605&rft_id=info:doi/10.1016/j.jcin.2014.07.023&rft_dat=%3Cproquest_pubme%3E1652434830%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p211t-89ee4872e5726c0003225d24b7d42ba0293fdf9a9c7f71cd5318361feca0e27a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1652434830&rft_id=info:pmid/25616822&rfr_iscdi=true |